Replies to post #409566 on Anavex Life Sciences Corp (AVXL)

[12x]

Good point. So 40M to run 1,000 patient p3/4 AD patient in US and 24M in AU. PD trial would be slightly cheaper. Anavex has the cash to complete both large AD and PD p3 trials. There is even less reason not to start the shorter duration PD p3 right away. PD provide the next best opportunity for a NDA.